2020 is officially here! In order to best prepare for the new year in patent policy, let's take a look at some top stories from 2019 with a lasting impact.

It’s the end of the year, and we at Juristat have a lot to celebrate! Along with growing our team and moving into a new office space, we launched new workflow automation solutions that generate office action responses and information disclosure statements using AI. And in the coming year, we’re rolling out a major update to our analytics product, giving clients improved access to comparison metrics, business intelligence, and custom reports for every tech center, art unit, USPC, or CPC class, and more.

Patents for Humanity is the USPTO awards competition recognizing inventors and innovators who develop game-changing technology to meet global humanitarian challenges. With the application deadline quickly approaching, we take a look at some of the past award recipients and celebrate their impact on society today.

Fiat Chrysler and Peugeot owner PSA Group recently announced the terms of a $48 billion merger that would create the world's fourth-largest automaker. A primary reason for the merger is to share the cost of developing electric and autonomous vehicles.

With concern growing about the United States’ ability to remain the dominant force in the global innovation economy, the STRONGER Patents Act is intended to restore and strengthen the U.S. patent system by making it easier for patent owners to enforce their intellectual property rights.

The next big technology shakeup is on its way. With a limited rollout in 2018 leading to a much more comprehensive release in 2020, 5G is here, with increased speeds, instantaneous communication, and the ability to connect just about everything.

The USPTO has announced its intention to extend the After Final Consideration Pilot (AFCP) 2.0 program through September 30, 2020. The program had been set to expire on September 30, 2019.

For patent applicants looking to move quickly, the USPTO's Track One program is a seemingly obvious choice. But does the program, which was instituted in 2011, still work? The answer is yes – but not like it used to.

Pfizer and Mylan, the maker of EpiPens, are merging. Pfizer will offload Upjohn, its portfolio of drugs that are no longer protected by patents, including Viagra, Lipitor and Celebrex, combining with rival Mylan to create a new company that will have a new, yet-to-be-announced name.

The USPTO recently hosted a webinar about the general approach to interpreting claims and how the specification interacts with and modifies those claims. With the goal of providing answers to common examiner questions, the webinar specifically discussed the importance of the broadest reasonable interpretation (BRI) of each claim, how to handle claim limitations, and the added difficulty of limitations related to 35 USC 112(f) (aka “Means-or-Step-Plus-Function” Limitations). The hope is to create consistent examination guidance that ensures all claims will be interpreted similarly by anyone of ordinary skill in the art.